Bromhexine Sunward

Bromhexine hydrochloride changes the structure of bronchial secretions and increases the volume and reduce the viscosity of sputum.

It is indicated in bronchitis and other respiratory conditions as an aid to expectoration.

Adult: 8 to 16 mg three or four times daily.
Children 2 to 5 years: 4 mg twice daily.
Children 5 to 10 years: 4 mg four times daily.
Administration: Oral administration.

It is contraindicated in patients who is hypersensitive to it and should be given cautiously to patients with gastric ulceration.

Bromhexine should be given cautiously to patients with gastric ulceration. An increase in volume of liquefied sputum should be expected.
In very few cases, severe skin disorders such as Stevens-Johnson’s syndrome and toxic epidermal necrolysis (TEN) have been reported after administration of mucolytic substances (e.g. bromhexine/ambroxol), which in most cases could be explained by the patient’s underlying disease and/or the concomitant medication. In addition during the early phase of a Steven-Johnson Syndrome or TEN a patient may first experience non-specific influenza-like prodromes (e.g. fever, aching body, rhinitis, cough and sore throat). It is possible that a symptomatic treatment is started with a cough and cold preparation due to these misleading nonspecific influenza-like prodromes. Therefore if new skin or mucosal lesions occur, medical advice should be sought immediately and treatment with bromhexine/ambroxol discontinued as a precaution.

The safe use of Bromhexine HCl has not been established with respect to the possible adverse effects upon foetal development. Therefore, it should not be used in women of child bearing potential, particularly during early pregnancy, or in lactating women unless advised by the physician.

Gastro-intestinal side effects may occur occasionally and a transient rise in serum amino-transferase values has been reported.

Bromhexine is known to enhance the penetration of erythromycin into bronchial secretions. It is also reported that addition of bromhexine to Cephalexin improved symptoms and ventilatory function in elderly patients treated for acute exacerbations of chronic bronchopulmonary disease.

Store at or below 25°C. Protect from light.
Shelf-Life: Elixir: 2 years. Tablet: 5 years.

Cough & Cold Preparations

R05CB02 - bromhexine ; Belongs to the class of mucolytics. Used in the treatment of wet cough.

POM